Research and Developments

Page 2 of 1912345...10...Last »

March 13, 2017

OpRegen® for Dry-AMD in Trials

Posted in: Latest News, Research and Developments

BioTime, Inc. is expanding its ongoing Phase I/IIa clinical trial for OpRegen® for treatment of dry AMD. by naming the first two sites that will treat patients in the U.S. Adi Mohanty, Co-Chief Executive Officer of BioTime, said, “We are honored to be working with two of the leading U.S. clinicians in ophthalmology, Dr. David
read more »

March 8, 2017

Further Evidence of the Value of In-Home Occupational Therapy

Posted in: Latest News, Low Vision Rehabilitation, Research and Developments

A new study, published in the March 8 edition of Investigative Ophthalmology & Visual Science, has concluded that low-vision patients who improve in their daily living activities through at-home training with an occupational therapist (OT) have less severe symptoms of depression than similar patients who did not receive such training. Using outcomes from a recently
read more »

February 15, 2017

Another Anti-VEGF Drug Falls Short

Posted in: Latest News, Research and Developments

by Dan Roberts We announced here in December 2016 that Fovista, Ophthotech’s once-promising experimental drug for treatment of wet macular degeneration, failed to show positive results in Phase 3 trials, resulting in a discontinuance of the research. Now, Ohr Pharmaceuticals has announced temporary suspension of a clinical study for its drug candidate, Squalamine, an eye
read more »

January 27, 2017

Trials beginning for Emixustat Treatment of Stargardt Disease

Posted in: Latest News, Research and Developments

Acucela has announced that the first patient has enrolled in a study to evaluate emixustat hydrochloride (“emixustat”) in subjects with Stargardt disease. Approximately 30 subjects will be enrolled at 4 to 6 clinical sites in the United States, with subjects taking oral doses of the drug once daily in the evening for one month. Emixustat
read more »

January 22, 2017

“How soon will my good eye go bad?”

Posted in: Latest News, Research and Developments

This is commonly-asked by people affected with unilateral age-related macular degeneration (AMD). AMD is a chronic and progressive disease, and the chances are good that it will eventually affect both eyes. The question about when that will happen has been addressed by a three-continent study published in January 2017 by the British Journal of Ophthalmology. Researchers
read more »

January 14, 2017

Researchers To Study Telescope Implant For Post-Cataract Patients

Posted in: Latest News, Research and Developments

VisionCare, Inc. has announced FDA approval to study the company’s Implantable Miniature Telescope (IMT) in patients who have been previously treated for cataract. In the study, the new intraocular lens will be removed and replaced with the IMT in order to evaluate the safety and effectiveness of the device. For the past 8 years, the telescope implant has been improving visual acuity and quality of life
read more »

January 6, 2017

Lucentis® Approved for Myopic Macular Degeneration

Posted in: Latest News, Research and Developments, Therapies, Treatments, and Procedures

Genentech has announced FDA approval for Lucentis® as a treatment for patients with choroidal neovascularization (CNV) resulting from myopic macular degeneration (MMD), also known as myopic degeneration. Severe myopia (near-sightedness) can cause uncorrectable central vision impairment, and it may advance to total central vision loss from CNV, which is growth and leakage of blood vessels
read more »

December 21, 2016

Fovista® Fails Final Test For Wet AMD Treatment

Posted in: Latest News, Research and Developments

Fovista®, a once-promising experimental drug for treatment of wet macular degeneration, has failed to show positive results in Phase 3 trials. This is surprising, since, on June 14, 2012, Ophthotech Corporation reported a 62% higher relative visual benefit when Fovista (1.5 mg) was used in combination with Lucentis in Phase 2b clinical trials. Based upon those
read more »

December 6, 2016

Photobiomodulation—A New Treatment For Dry AMD?

Posted in: Latest News, Research and Developments

A new non-invasive technology from LumiThera Inc. may help improve vision in  people with dry age-related macular degeneration. Photobiomodulation involves exposure of the retina to light from diodes emitting red, yellow, and infrared wavelengths. Researchers in Switzerland and Toronto recently found that treating eyes three times a week for three weeks improved best corrected visual
read more »

November 22, 2016

Eye Drops for Wet AMD Showing Positive Results

Posted in: Latest News, Research and Developments

Eye drops continue to show promise as future treatments for wet AMD and other eye diseases involving blood vessel growth and hemorrhaging in the retina. In a presentation at the 2015 Ophthalmology Innovation Summit at the American Academy of Ophthalmology. Paul G. Chaney (President and CEO of Panoptica) reported preliminary results from the PAN-90806 clinical
read more »

Page 2 of 1912345...10...Last »

Custom Wordpress design and web development by Jeff Roberts Web Design

WP-Backgrounds by InoPlugs Web Design and Juwelier Schönmann